Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

155.56 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Michael Mahoney Turned Boston Scientific Into A Medical Tech Empire
Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted. 
Via Investor's Business Daily
3 Elite High-Yield Dividend Stocks Down 8% to 27% That Have Hiked Their Payouts for More than 50 Years in a Row
Via The Motley Fool
Topics Bonds
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
From Johnson & Johnson
Via Business Wire
P/E Ratio Insights for Johnson & Johnson
Via Benzinga
Why Is Teva Stock Trading Higher On Tuesday?
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga
Why Dan Loeb Just Made Kenvue One Of His Top Holdings
Activist investor Dan Loeb's Third Point LLC acquired a significant stake in consumer health company Kenvue Inc. in Q1 2025. 
Via Benzinga
1 Top Dividend Stock to Buy for a Lifetime of Passive Income
Via The Motley Fool
Topics Economy Lawsuit
Johnson & Johnson (NYSE:JNJ) – A Reliable Dividend Stock Worth Considering
Johnson & Johnson (NYSE:JNJ) offers a strong dividend yield, consistent growth, and solid profitability, making it a compelling choice for income investors. 
Via Chartmill
Investing for Passive Income? Here's What History Says About the Stability of Dividend King Stocks.
Via The Motley Fool
Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond
Via The Motley Fool
Topics Bonds Stocks
Elon Musk Commits to Tesla. Is That a Good Thing?
Via The Motley Fool
Value Investing Is Not Dead - It Just Got Smarter
Via Benzinga
FDA Panel Reiterates the Cancer Risks of Talc
From Beasley Allen Law Firm
Via Business Wire
This Healthy High-Yielding Dividend Stock Just Increased Its Payment for the 48th Year in a Row
Via The Motley Fool
Topics World Trade
3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market
For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider 
Via MarketBeat
Topics ETFs Economy
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
From Johnson & Johnson
Via Business Wire
Apple, Nvidia, GM: CEOs Are Talking About Being American-Made Again
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys.... 
Via Benzinga
Market Whales and Their Recent Bets on JNJ Options
Via Benzinga
Meet the Warren Buffett Investment That's Gained 5,502,284% and Looks Set to Soar Even Higher
Warren Buffett has had a lot of successful investments, but one in particular has crushed the stock market time and again. 
Via The Motley Fool
3 Magnificent Stocks That Are Passive Income Machines
Via The Motley Fool
US-China Trade Truce, Trump's Middle East Deals Spark Wall Street Rally: This Week In Markets
U.S. and China cut tariffs by 115 points, sparking a stock rally and improving trade outlook. Trump secures $2 trillion in Gulf deals. 
Via Benzinga
Topics Government World Trade
Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails
From Nachawati Law Group
Via Business Wire
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity. 
Via Benzinga
Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets
Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru. 
Via Benzinga
Topics Bonds
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up
CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26. 
Via Benzinga
The Smartest Dividend Stocks to Buy With $5,000 Right Now
Via The Motley Fool
Topics Economy Retirement
Trump Unveils 'Historic And Transformative' $600 Billion Saudi Deal, Predicts Markets Will 'Go A Lot Higher'
President Trump unveils a $600 billion Saudi investment package into the U.S., with major deals in tech, defense, energy, and healthcare. 
Via Benzinga
Topics Government
13 Analysts Have This To Say About Johnson & Johnson
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS